Dose Insider / Glossary / STEP TEENS

STEP TEENSThe trial of semaglutide in teenagers with obesity

Updated November 20, 2026 · 3 min read · Weghuber et al., N Engl J Med 2022; WEGOVY label

STEP TEENS is the trial that led to the approval of Wegovy for adolescents.

−16.1%Semaglutide 2.4 mg, change in BMI by week 68
Change in BMI by week 68Adolescents aged 12 to 17, %Semaglutide 2.4 mg−16.1%Placebo+0.6%Change in BMI by week 68Adolescents aged 12 to 17, %Semaglutide 2.4 mg−16.1%Placebo+0.6%

73% on semaglutide lost at least 5% of their weight, against 18% on placebo.

On this page

It enrolled 201 young people aged 12 to 17 with obesity, or with overweight and a weight-related condition, and gave them semaglutide 2.4 mg or placebo once a week for 68 weeks, alongside a lifestyle program. Body mass index fell by 16.1% on semaglutide and rose by 0.6% on placebo. It was published in the New England Journal of Medicine in 2022.1

How the trial was run

The trial used percentile charts rather than a fixed body mass index. It enrolled adolescents with a body mass index at or above the 95th percentile, which is obesity, or at or above the 85th percentile with at least one weight-related condition. In practice all but one participant had obesity. Two in three were assigned to semaglutide.1

The main outcome was the percentage change in body mass index, not in weight, since teenagers are still growing. The main confirmatory secondary outcome was a weight loss of at least 5%.1 Of the 201 enrolled, 180, or 90%, completed treatment.

What it found

Weghuber et al., 2022.1

The Wegovy label reports the same trial by body mass index thresholds. The groups started from an average body mass index of 37.7 on semaglutide and 35.7 on placebo. A fall of at least 5% was reached by 77.1% against 19.7%, at least 10% by 65.1% against 7.7%, and at least 15% by 57.8% against 4%.2 More than half of the teenagers on semaglutide lowered their body mass index by 15% or more.

On the basis of this trial, the Wegovy injection is approved for weight management in children aged 12 and older with obesity, with a maintenance dose of 2.4 mg, or 1.7 mg if needed. The tablet is not approved for anyone under 18.2

Side effects and safety

Weghuber et al., 2022.1

The Wegovy label gives the most frequent reactions in the teenage trial: nausea in 42% on the drug against 18% on placebo, vomiting in 36% against 10% and diarrhea in 22% against 19%. Abdominal pain, constipation, belching, reflux, indigestion and gas were also more common on the drug.2 The label lists acute gallbladder disease among its warnings for all ages. Our page on nausea on a GLP-1 covers what helps with the most common complaint.

For families

The size of the effect in teenagers was large: a 16.1% fall in body mass index over 68 weeks. In STEP 1, over the same 68 weeks, adults lost 14.9% of their weight; the two measures are not the same, since teenagers are still growing, but both point to a substantial effect.3 The trial does not answer questions that matter for a young person: effects over many years of growth, and what happens after stopping. For adults, the STEP 4 trial found that most of the lost weight came back within a year of switching to placebo.4

Limits

The trial was small, at 201 participants, lasted 68 weeks and was funded by Novo Nordisk, the maker of semaglutide. It did not include children younger than 12.1

Sources

  1. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity (STEP TEENS). N Engl J Med 2022;387:2245-2257. Funded by Novo Nordisk; NCT04102189. doi:10.1056/NEJMoa2208601
  2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1, 2, 5, 8.4 and 14. accessdata.fda.gov
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. doi:10.1056/NEJMoa2032183
  4. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA 2021;325:1414-1425. doi:10.1001/jama.2021.3224

Related analyses

Log doses, weight and symptoms together, with a view a parent can follow.

Open Dose Insider